
The funds will be used to drive the development, approval and market launch of its proprietary P.L.E.A.S.E.® (Painless Laser Epidermal System) platform that enables needle-free and painless administration of biopharmaceutical drugs, in varying and individualised dosages, through partnered patch technology.
In conjunction with the investment, Dr. Manfred Asamer, CEO of Asamer Holding AG, and Dr. Werner Lanthaler, the current CEO of Evotec and the ex-CFO of Intercell, will join the company’s board.
FinSMEs
20/07/2010